Abstract
The wealth of literature relating to the triazenes amounts, according to the Chemical Abstracts Service, to some 1200 papers over the past twenty years, of which many relate to the antitumour action of these compounds. Thus it is necessary to be selective in the choice of topics for a review of this nature. The object therefore is to attempt to show how the in vivo antitumour test results of these compounds have given an insight into their mode of action and the structural requirements for it, and led to the choice of clinical agents. Some significant observations have so far been largely ignored and these will be highlighted. Finally the activity of some triazene N-oxides will be discussed together with their potential application.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
P. Griess, Uber eine neue Klasse organischer Verbindungen in denen Wasserstoff durch Stickstoff vertreten ist, Ann. Chem., 121: 257–280 (1862).
A. Baeyer and C. Jaeger, Ueber die Amide des Diazobenzols, Ber., 8: 148–151 (1875).
H. Druckrey, Specific carcinogenic and teratogenic effects of “indirect” alkylating methyl and ethyl compounds and their dependency on stages of oncogenic development, Xenobiotica, 3: 217–303 (1973).
D.A. Clarke, R.K. Barclay, C.C. Stock and C.S. Rondestvedt, Triazenes as Inhibitors of Mouse Sarcoma 180, Proc. Soc. Exptl. Biol. Med., 90: 484–489 (1955).
J.H. Burchenal, M.K. Dagg, M. Beyer and C.C. Stock, Chemotherapy of Leukemia VII. Effect of substituted triazenes on transplanted mouse leukemia, Proc. Soc. Expt. Biol. Med., 91: 398–401 (1956).
H. Foerster and D. Steinhoff, Cytostatic mono- and bis-dialkyl triazenes, South African Pat. 69 04,895, Chem. Abs., 73, 55823 (1970).
Uniroyal Inc., Substituted triazenes as pre-emergent herbicides, Brit. Pat. 1,130,469, Chem. Abs., 70, 19788 (1969).
M. Mazza, G. Pagani, G. Calderara and L. Vicarini, Phytotoxic activity of triazene derivatives. I. 1-Phenyl-3,3-dialkyltriazenes phenyl-substituted with alkyl, halo or nitro groups, Farmaco, Ed. Sci., 28: 846–861 (1973).
Y.F. Shealy, R.F. Struck, L.B. Holum and J.A. Montgomery, Synthesis of potential anticancer agents. XXIX. 5-Diazoimidazole-4-carboxamide and 5-diazo-v-triazole-4-carboxamide, J. Org. Chem., 26: 2396–2401 (1961).
J.A. Montgomery, Experimental studies at Southern Research Institute with DTIC (NSC-45388), Cancer Treat. Rept., 60: 125–134 (1976).
Y.F. Shealy, C.A. Krauth and J.A. Montgomery, Imidazoles. I. Coupling reactions of 5-diazoimidazole-4-carboxamide (NSC-82196), J.Org.Chem., 27: 2150–2154 (1962).
Y.F. Shealy and C.A. Krauth, Complete inhibition of mouse leukaemia L1210 by 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4 (or 5)-carboxamide, Nature, 210: 208–209, (1966).
Y.F. Shealy, Triazenylimidazoles and related compounds, Adv. in Med. Oncol. Res. Educ.: Proc. Int. Cancer Congress 12th, Pergamon, Oxford, Vol 5: 49–58 (1978).
D.W. Miles and R.L. Souhami, Chemotherapy of metastatic disease, Bailtière’s Clin. Oncol, 1: 551–573 (1987).
I. Kline, R.J. Woodman, M. Gang and J.M. Venditti, Effectiveness of antileukemia agents in mice inoculated with leukemia L1210 variants resistant to 5-(3,3-dimethyl-1-triafceno)imidazole-4-carboxamide (NSC-45388) or 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196), Cancer Chemother. Repts, 55: 9–28 (1971).
Y.F. Shealy, C.A. Krauth, C.E. Opliger, H.W. Guin and W.R. Laster, Triazenes of phenylbutyric, hydrocinnamic, phenoxyacetic and benzoylglutamic acid derivatives, J. Pharm. Sci., 60: 1192–1198 (1971).
Y.F. Shealy, C.A. O’Dell, J.D. Clayton and C.A. Krauth, Benzene analogues of triazenoimidazoles, J. Pharm. Sci., 60: 1462–1468 (1971).
T.A. Connors, P.M. Goddard, K. Merai, W.C.J. Ross and D.E.V. Wilman, Tumour inhibitory triazenes: structural requirements for an active metabolite, Biochem. Pharmacol., 25: 241–246 (1976).
R.C.S. Audette, T.A. Connors, H.G. Mandel, K. Merai and W.C.J. Ross, Studies on the mechanism of action of the tumour inhibitory triazenes, Biochem. Pharmacol., 22: 1855–1864 (1973).
G.J. Hatheway, C. Hansen, K.H. Kim, S.R. Milstein, C.L. Schmidt and R.N. Smith, Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. I. Quantitative structure-activity relationships vs. L1210 leukemia in mice, J. Med. Chem., 21: 563–574 (1978).
C. Hansch, G.J. Hatheway, F.R. Quinn and N. Greenberg, Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 2. On the role of correlation analysis in decision making in drug modification. Toxicity quantitative structure-activity relationships of 1-(X-phenyl)-3,3-dialkyltriazenes in mice, J. Med. Chem., 21: 574–577 (1978).
D. Farquhar and J. Benvenuto, 1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) J. Med. Chem., 27: 1723–1727 (1984).
V.A. Levin, Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability, J. Med.Chem., 23: 682–684 (1980).
D.E.V. Wilman, N.J. Bradley and S.G. Richardson, Astrocytoma xenografts in the choice of a second-generation triazene, Brit. J. Cancer, 50: 277 (1984).
G.J. Atwell, B.F. Cain and W.A. Denny, Potential antitumor agents. 22. Latentiated congeners of the 4’-(9-acridinyl-amino)methanesulfonanilides, J. Med.Chem., 20: 520–526 (1977).
G. Abel, T.A. Connors, P. Goddard, H. Hoellinger, N.-H. Nam, L. Pichat, W.C.J. Ross and D.E.V. Wilman, Cytotoxic sulphonamides designed for selective deposition in malignant tissues, Europ. J. Cancer, 11: 787–793 (1975).
A.J. Lin and T.L. Loo, Synthesis and antitumor activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines, J. Med. Chem., 21: 268–272 (1978).
B.S. Ashby, pH Studies in human malignant tumours, Lancet, ii: 312–315 (1966).
C.D. Stevens, M.A. Wagner, P.M. Quinlin and A.M. Kock, Localization of sulfapyrazine in cancer tissue on glucose injection, Cancer Res., 12: 634–639 (1952).
G. Abel, T.A. Connors, W.C.J. Ross, N.-H. Nam, H. Hoellinger and L. Pichat, The selective concentration of sulphadiazine and related compounds in malignant tissue, Eur. J. Cancer, 9: 49–54 (1973).
N. Calvert, T.A. Connors and W.C.J. Ross, Aryl-2-halogenoalkylamines XXV. Derivatives of sulphanilamide designed for selective deposition in neoplastic tissue. Europ. J. Cancer, 4: 627–636 (1968).
S.M. Sieber and R.A. Adamson, Selection of carriers for alkylating moieties to increase their antitumor specificity, Cancer Treatment Rep., 60: 217–219 (1976).
R.E. Counsell, P. Pocha, J.O. Morales and W.H. Beierwaltes, Tumor localizing agents III. Radioiodinated quinoline derivatives, J. Pharm. Sci., 56: 1042–1044 (1967).
E. Bonmassar, A. Bonmassar, S. Vadlamudi and A. Goldin, Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug, Proc. Natl. Acad. Sci. U.S., 66: 1089–1095 (1970).
F.A. Schmid and D.J. Hutchison, Decrease in oncogenic potential of L1210 leukemia by triazenes, Cancer Res., 33: 2161–2165 (1973).
A. Nicolin, F. Spreafico, E. Bonmassar and A. Goldin, Antigenic changes of L5178Y lymphoma after treatment with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide in vivo, J. Nat. Cancer Inst., 56: 89–93 (1976).
A. Nicolin, M. Cavalli, A. Missiroli and A. Goldin, Immunogenicity induced in vivo by DIC in relatively non-immunogenic leukemias, Europ. J. Cancer, 13: 235–239 (1977).
T. Giraldi, A.M. Guarino, C. Nisi and G. Sava, Antitumor and antimetastatic effects of benzenoid triazenes in mice bearing Lewis lung carcinoma, Pharmacol. Res. Commun., 12: 1–11 (1980).
D.J. Kohlsmith, K. Vaughan and S.J. Luner, Triazene metabolism. III. In vitro cytotoxicity towards M21 cells and in vivo antitumor activity of the proposed metabolites of the antitumor 1-aryl-3,3-dimethyltriazenes, Can.J.Physiol.Pharmacol., 62: 396–402 (1984).
K. Vaughan, Y. Tang, G. Llanos, J.K. Horton, R.J. Simmonds, J.A. Hickman and M.F.G. Stevens, Studies of the mode of action of anti-tumor triazenes and triazines. 6. 1-Aryl-3-hydroxymethyl-1-methyltriazenes: synthesis, chemistry and anti-tumor properties, J. Med. Chem., 27: 357–363 (1984).
L.M. Cameron, R.J. LaFrance, C.M. Hemes, K. Vaughan, R. Rajaraman, D.C. Chubb and P.M. Goddard, Triazene metabolism IV. Derivatives of hydroxymethyltriazenes: potential prodrugs for the active metabolites of the antitumour triazene, DTIC, Anti-Cancer Drug Des., 1: 27–36, (1985).
K. Vaughan, K.U.K. Gamage Nicholas, R.D. Singer, M. Roy and N.W. Gibson, Triazene metabolism. VI. 3-Azidomethyl-3-alkyl-1-aryltriazenes, a new class of antitumour triazene with potential pro-drug applications, Anti-Cancer Drug Des., 2: 279–287 (1987).
K. Vaughan, H.W. Manning, M.P. Merrin and D.L. Hooper, Open chain nitrogen compounds. Part XIII. 1-Aryl-3-arylthio-methyl-3-methyltriazenes and 3-(arylazo)-1,3-thiazolidines, Can. J. Chem., 66: 2487–2491 (1988).
J. Hey, E. Rosa and L. Fernandes, Triazene drug metabolites. Part 5. A simple direct synthesis of 3-alkoxymethyl- and 3-alkylthiomethyl-1-aryl-3-alkyltriazenes from l-aryl-3-hydroxymethyl-3-alkyltriazenes, J. Chem. Research (S), 264–265 (1987).
F.K. Hess, P.A. Stewart, G. Possanza and K. Freter, Immunosupressive 1-phenyl-3-hydroxy-3-methyltriazenes, Ger. Patent, 2,208,368, Chem. Abs., 79: 146271 (1973).
J.L. Miesel, 3,3-Dialkyl-l-(substitutedphenyl)triazene-1-oxides, U.S. Patent, 3,989,680 (1976).
J.L. Miesel, 3-Aryltriazene 1-oxides for treating inflammatory diseases, U.S. Patent, 3,962,434 (1976).
S. Neidle and D.E.V. Wilman, Unpublished data.
K. Freter, F. Hess and K. Grozinger, Acylierung von Hydroxy-phenyl-triazenes, eine neuartige Umlagerung, Ann.Chem., 811–820 (1973).
A.G. Giumanini, L. Lassiani, C. Nisi, A. Petrie and B. Starovnik, The structure of aryldialkyltriazene N-oxides, Bull.Chem.Soc.Jpn., 56: 1887–1888 (1983).
R. Kuroda and D.E.V. Wilman, 3-(4-Carbamoylphenyl)-1-methyltriazene 1-oxide, Acta Cryst., C41: 1543–1545 (1986).
S. Neidle, G.D. Wehster, R. Kuroda and D.E.V. Wilman, Synthesis and structure of 3-(4-carbamoylphenyl)-1,3-dimethyltriazene 1-oxide, Acta Cryst., C43: 674–676 (1987).
D.E.V. Wilman and P.M. Goddard, Triazene N-oxides. 2. Synthesis and antitumour activity of some triazene 1-oxides, Prog. in Pharmacol. Clin. Pharmacol., in press.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media New York
About this chapter
Cite this chapter
Wilman, D.E.V. (1990). Triazenes and Triazene N-Oxides: Antitumour Action in Animal Tumour Systems. In: Giraldi, T., Connors, T.A., Cartei, G. (eds) Triazenes. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3832-5_3
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3832-5_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6710-9
Online ISBN: 978-1-4615-3832-5
eBook Packages: Springer Book Archive